Case report

Acute thrombocytopenia after De-Nol

I J BECKINGHAM, G BAIRD, AND P J L KESTEVEN
From the Department of Haematology, Freeman Hospital, Newcastle-upon-Tyne

SUMMARY We describe a case of severe acute thrombocytopenia in a 72 year old man treated with De-Nol for erosive biliary gastritis.

A 72 year old man is reported with a two day history of painful haemorrhagic mouth ulcers and recurrent epistaxes. In 1968 vagotomy and pyloroplasty had been performed for duodenal ulceration, but he continued to suffer intermittent dyspepsia, treated with antacids and on one occasion a short course of De-Nol, eight years previously. De-Nol is a bismuth chelate (tripotassium dicitrato bismuthate) used in the treatment of peptic ulcers. It works by binding to mucus and increasing the resistance to back diffusion of hydrogen ions, and is also thought to stimulate production of protective prostaglandins. Adverse reactions to De-Nol are infrequent and usually mild.

Case report

Two weeks before admission after an exacerbation of peptic symptoms, a gastroscopy showed extensive erosive biliary gastritis, with fresh blood loss. A full blood count at that time was normal: Hb 14.0 g/dl; WBC 7.5×10^9/l; and platelets 350×10^9/l. De-Nol (two tablets tid) was prescribed. He was taking no other medications.

On admission he was apyrexial and had evidence of widespread bleeding: oral haemorrhagic vesicles; widespread petechiae; epistaxes; melaena and fresh blood per rectum; and microscopic haematuria. A full blood count revealed severe thrombocytopenia: the platelet count was <10^9/l. The remainder of his FBC was normal (Hb 14.3 g/dl, WBC 9.0×10^9/l). Morphology of the blood film, full coagulation screen, and biochemical profile (electrolytes, LFTs) were also normal. Acute and convalescent viral titres were not raised. Bone marrow showed hypoplasia with absent megakaryocytes, although morphology of other cell lines was normal and no infiltrations were seen. The De-Nol was stopped and he received oral prednisolone (5 mg tid) and daily platelet transfusions. Four days after admission the bleeding stopped and no new petechiae developed. On the 10th day the platelet count had risen to 62×10^9/l and two days later to 320×10^9/l. A repeat bone marrow biopsy showed normal haemoipoietic tissue with increased numbers of megakaryocytes. No further bleeding occurred and the platelet count remained within the normal range at subsequent follow up.

Discussion

It is a common misconception that De-Nol is not absorbed from the gastrointestinal tract. Bismuth has been shown to be absorbed after De-Nol therapy in minute quantities, reaching a mean blood concentrations of approximately 7 µg/l after four weeks' treatment. Although this is well below the proposed toxic threshold of 100 µg/l, it is possible that the widespread erosive lesions in this patient facilitated increased absorption of bismuth. Alternatively, absorbed bismuth even in a low concentration may be enough to induce an idiosyncratic drug reaction.

Acute thrombocytopenia has not previously been reported as an adverse reaction after De-Nol treatment. The temporal relationship of drug administration, the severity of symptoms, and the rapid recovery of the bone marrow after withdrawal of the De-Nol in this patient suggests an idiosyncratic drug reaction.

This reaction has been reported to the manufacturers and to the CSSM.
Acute thrombocytopenia after De-Nol

References
Acute thrombocytopenia after De-Nol.

I J Beckingham, G Baird and P J Kesteven

_Gut_ 1989 30: 1016-1017
doi: 10.1136/gut.30.7.1016

Updated information and services can be found at:
http://gut.bmj.com/content/30/7/1016

_These include:_

**Email alerting service**
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
_Stomach and duodenum_ (1689)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/